These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 2965123)

  • 41. [Treatment of commonly occurring skin infections].
    Hyry H; Lumio J; Kuokkanen K
    Duodecim; 1995; 111(8):697-702. PubMed ID: 8681829
    [No Abstract]   [Full Text] [Related]  

  • 42. Teicoplanin for therapy of gram-positive infections in neutropenic patients.
    Verhagen C; De Pauw BE
    Int J Clin Pharmacol Res; 1987; 7(6):491-8. PubMed ID: 2964418
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of skin and soft tissue infections with oral ciprofloxacin.
    Fass RJ
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():153-7. PubMed ID: 3804903
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Teicoplanin--domiciliary use in surgical infections.
    Rubinstein E
    Eur J Surg Suppl; 1992; (567):27-9. PubMed ID: 1381638
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bacterial infections of the skin. I: primary and secondary infections.
    Chan HL
    Ann Acad Med Singap; 1983 Jan; 12(1):92-7. PubMed ID: 6859802
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cellulitis syndromes: an update.
    Baddour LM
    Int J Antimicrob Agents; 2000 Mar; 14(2):113-6. PubMed ID: 10720800
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ceftazidime versus tobramycin plus ticarcillin in the treatment of soft-tissue infections.
    Solomkin JS; Cocchetto DM
    Clin Ther; 1986; 9(1):123-34. PubMed ID: 3545476
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of cefonicid and cefazolin for treatment of soft-tissue infections.
    Slutkin G; Marzouk J; Dall L; Mills J
    Rev Infect Dis; 1984; 6 Suppl 4():S853-6. PubMed ID: 6395276
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Teicoplanin--a new agent for gram-positive bacterial infections.
    Eggleston M; Ofosu J
    Infect Control Hosp Epidemiol; 1988 May; 9(5):209-11. PubMed ID: 2967322
    [No Abstract]   [Full Text] [Related]  

  • 50. Teicoplanin in the treatment of gram-positive-bacterial endocarditis.
    Martino P; Venditti M; Micozzi A; Brandimarte C; Gentile G; Santini C; Serra P
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1329-34. PubMed ID: 2529815
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of a glycopeptide antibiotic, teicoplanin, in the treatment of septicaemia caused by gram-positive bacteria.
    Webster A; Wilson AP; Treasure T; Grüneberg RN
    Int J Clin Pharmacol Res; 1988; 8(2):95-8. PubMed ID: 2967800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Red man syndrome with teicoplanin.
    Dubettier S; Boibieux A; Lagable M; Crevon L; Peyramond D; Milon H
    Rev Infect Dis; 1991; 13(4):770. PubMed ID: 1833809
    [No Abstract]   [Full Text] [Related]  

  • 53. The use of a new glycopeptide antibiotic, teicoplanin, in the treatment of bacterial endocarditis.
    Webster A; Wilson AP; Williams AH; Treasure T; Grüneberg RN
    Postgrad Med J; 1987 Aug; 63(742):621-4. PubMed ID: 2962071
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.
    Seltzer E; Dorr MB; Goldstein BP; Perry M; Dowell JA; Henkel T;
    Clin Infect Dis; 2003 Nov; 37(10):1298-303. PubMed ID: 14583862
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The use of teicoplanin in neutropenic patients: values and limits].
    Espinouse D; Chomarat M
    Pathol Biol (Paris); 1990 Jun; 38(5 ( Pt 2)):552-6. PubMed ID: 2143573
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical evaluation of the use of teicoplanin for staphylococcal infections in immunocompetent and immunodepressed patients].
    Catania S; Trinchieri V; Lanzalone CM; Causo T; Allegra C; Catania N; Cirelli A
    Riv Eur Sci Med Farmacol; 1990 Dec; 12(6):319-24. PubMed ID: 2151886
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison of the new topical antibiotic mupirocin ('Bactroban') with oral antibiotics in the treatment of skin infections in general practice.
    Villiger JW; Robertson WD; Kanji K; Ah Chan M; Fetherston J; Hague IK; Haycock D; Hunter P
    Curr Med Res Opin; 1986; 10(5):339-45. PubMed ID: 3102167
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cephalosporins in cutaneous infections. A prospective comparison of two dosage regimens of ceftazidime for therapy of skin and skin structure infections.
    Parish LC; Witkowski JA; Snow R; Eron L; Mogabgab WJ
    Int J Dermatol; 1986 May; 25(4):258-65. PubMed ID: 3519482
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.